+ All Categories
Home > Documents > Tratamiento Del Trastorno Bipolar en Embarazo

Tratamiento Del Trastorno Bipolar en Embarazo

Date post: 04-Mar-2016
Category:
Upload: claudio-andres-araya
View: 9 times
Download: 0 times
Share this document with a friend
Description:
Revisión de papers y trabajos actuales sobre el tratamiento psicofarmacológico del Trastorno Bipolar en Embarazo

of 18

Transcript

Tratamiento del Trastorno Bipolar en Embarazo

Tratamiento del Trastorno Bipolar en EmbarazoRevisin de PapersDr. Claudio A. ArayaResidencia de Psiquiatra - SBMFirst-line monotherapy options remain the mood stabilizers lithium and divalproex, and the atypical antipsychotics risperidone, olanzapine, standard and extended-release (XR, ER) quetiapine, ziprasidone, and aripiprazole. The 2013 update added divalproex ER, asenapine, and paliperidone ER as other recommended first-line agents. Certain clinical features may guide medication choices in individual patients. For example, lithium may be more effective in cases of classic euphoric mania, while mixed episodes or a history of rapid cycling may favour divalproex. Atypical anti psychotics may be more effective in mixed mania and are particularly favoured when agitation or psychosis is present. Also remaining as first-line therapy is a combination of a mood stabilizer and an atypical antipsychotic, which has been demonstrated to provide more rapid efficacy with approximately 20% higher response rates than with a mood stabilizer alone.Tratamiento del TBCANMAT 2013 Update of Guidelines for the Management of Patients with Bipolar DisorderTratamiento agudo para Episodio Manaco

Tratamiento del TBCANMAT 2013 Update of Guidelines for the Management of Patients with Bipolar DisorderTratamiento agudo para Depresin Bipolar IThere were no changes in first-line maintenance therapy options: lithium, lamotrigine (effective only in preventing relapse into depression), divalproex, olanzapine, quetiapine, long-acting injectable (LAI) risperidone, and aripiprazole. First-line combinations remain adjunctive lithium or divalproex + quetiapine, LAI risperidone, aripiprazole, or ziprasidone. Evidence remains strong for lithium, lamotrigine, olanzapine, and (to a lesser degree) divalproex. For second-line treatment, palideridone ER is added to carbamazepine as monotherapy. Combination therapy remains unchanged from the 2009 update: lithium + one of divalproex, carbamazepine, olanzapine, risperidone, or lamotrigine, divalproex + olanzapine, and olanzapine + fluoxetine. Tratamiento del TBCANMAT 2013 Update of Guidelines for the Management of Patients with Bipolar DisorderTratamiento de mantenimiento TBIThere were few changes in the updated guideline recommendations for the treatment of acute BD-II depression. Quetiapine remains the only first-line mono - therapy; the XR version is added to the standard form. Second-line therapy is identical to the previous update: lithium, lamotrigine, divalproex, lithium or divalproex + antidepressants, lithium + divalproex, and atypical antipsychotics + antidepressants. The new options for third-line care include quetiapine + lamotrigine and adjunctive ECT, N-acetylcysteine or triiodothyronine, which were added to antidepressant monotherapy (primarily for those with infrequent hypomanias) and alternate antidepressants. Tratamiento del TBCANMAT 2013 Update of Guidelines for the Management of Patients with Bipolar DisorderTratamiento Agudo para TBIIFor maintenance therapy in BD-II, quetiapine was added to existing first-line options lithium and lamotrigine. Adjunctive quetiapine and lamotrigine are the new elements in second-line therapy, joining divalproex, combination lithium or divalproex or atypical antipsychotic + antidepressant, and combination of 2 of lithium, divalproex, or an atypical antipsychotic. Fluoxetine is the latest third-line option with carbamazepine, oxcarbazepine, atypical antipsychotics, and ECT.

Tratamiento del TBCANMAT 2013 Update of Guidelines for the Management of Patients with Bipolar DisorderTratamiento de Mantenimiento para TBIIAtypical Antipsychotic Administration During Late Pregnancy: Placental Passage and Obstetrical Outcomes(Am J Psychiatry 2007; 164:12141220)

Mood stabilizers in pregnancy: a systematic review(Australian and New Zealand Journal of Psychiatry)Recomendaciones:cido flico 5 mg un mes previo a la concepcin y durante el 1er trimestreEstudios en embarazo temprano para determinar malformaciones (ecografa de alta resolucin para determinar translucidez nucal, biopsia de vellosidades coriales)Litio: elevado riesgo de malformaciones cardiovasculares. Ecocardiograma fetal y ecografa de alta resolucin a las 16 semanasMood stabilizers in pregnancy: a systematic review(Australian and New Zealand Journal of Psychiatry)

Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies(Early Human Development 88 (2012) 375378)Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies(Early Human Development 88 (2012) 375378)The children are developing normally after being exposed to lithium in utero and that no major developmental problems have evolved. This supports the thesis that continuing lithium therapy during pregnancy does not adversely affect the development of a child, and that it is rather safe to do so.This information may provide the counseling doctor and the bipolar woman more confidence in planning a safe pregnancy and continuing lithium treatment.Tratamiento farmacolgico de la depresin unipolar durante embarazo y lactancia

Tratamiento farmacolgico de la depresin unipolar durante embarazo y lactancia

Treatment of Bipolar Disorders during pregnancy: maternal and fetal safety and challenges Drug Healthcare and Patient Safety (24 dec. 2014)


Recommended